CY1117238T1 - Θεραπεια στρεπτοκοκκικων λοιμωξεων - Google Patents

Θεραπεια στρεπτοκοκκικων λοιμωξεων

Info

Publication number
CY1117238T1
CY1117238T1 CY20161100176T CY161100176T CY1117238T1 CY 1117238 T1 CY1117238 T1 CY 1117238T1 CY 20161100176 T CY20161100176 T CY 20161100176T CY 161100176 T CY161100176 T CY 161100176T CY 1117238 T1 CY1117238 T1 CY 1117238T1
Authority
CY
Cyprus
Prior art keywords
streptococcus pneumoniae
treatment
streptococcal infections
infection
sufficiently high
Prior art date
Application number
CY20161100176T
Other languages
English (en)
Inventor
Philippe Denoel
Philippe Vincent Hermand
Steve Labbe
Jan Poolman
Stephane Rioux
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of CY1117238T1 publication Critical patent/CY1117238T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αποκαλύπτει μια μέθοδο θεραπείας ή πρόληψης μιας λοίμωξης από Streptococcus pneumoniae (στρεπτόκοκκο της πνευμονίας) όπου η λοίμωξη από Streptococcus pneumoniae λαμβάνει χώρα σε ένα περιβάλλον όπου η ελεύθερη συγκέντρωση Ζn2+ και/ή Μn2+ είναι επαρκώς χαμηλή για να αυξορρυθμίσει την έκφραση τουλάχιστον μιας πρωτεΐνης PhtX (για παράδειγμα της PhtD) στον Streptococcus pneumoniae, η οποία περιλαμβάνει τη βαθμίδα χορήγησης μιας φαρμακευτικώς αποτελεσματικής ποσότητας πρωτεΐνης PhtX σε ασθενή άνθρωπο.
CY20161100176T 2010-03-09 2016-03-01 Θεραπεια στρεπτοκοκκικων λοιμωξεων CY1117238T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1003920.4A GB201003920D0 (en) 2010-03-09 2010-03-09 Method of treatment
EP11706840.3A EP2544711B1 (en) 2010-03-09 2011-03-08 Treatment of streptococcal infections

Publications (1)

Publication Number Publication Date
CY1117238T1 true CY1117238T1 (el) 2017-04-05

Family

ID=42136723

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20161100176T CY1117238T1 (el) 2010-03-09 2016-03-01 Θεραπεια στρεπτοκοκκικων λοιμωξεων

Country Status (24)

Country Link
US (2) US20120328659A1 (el)
EP (1) EP2544711B1 (el)
JP (1) JP5968229B2 (el)
KR (1) KR20130038237A (el)
CN (1) CN102869376A (el)
AU (1) AU2011226119B2 (el)
BR (1) BR112012022360A2 (el)
CA (1) CA2791946A1 (el)
CY (1) CY1117238T1 (el)
DK (1) DK2544711T3 (el)
EA (1) EA023702B1 (el)
ES (1) ES2562979T3 (el)
GB (1) GB201003920D0 (el)
HR (1) HRP20160150T1 (el)
HU (1) HUE027103T2 (el)
MX (1) MX2012010386A (el)
PL (1) PL2544711T3 (el)
PT (1) PT2544711E (el)
RS (1) RS54593B1 (el)
SG (1) SG183474A1 (el)
SI (1) SI2544711T1 (el)
SM (1) SMT201600059B (el)
WO (1) WO2011110570A1 (el)
ZA (1) ZA201206636B (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1343895B1 (en) * 2000-12-21 2008-06-18 ID Biomedical Corporation Streptococcus pyogenes antigens and corresponding dna fragments
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
US20140193451A1 (en) * 2012-10-17 2014-07-10 Glaxosmithkline Biologicals Sa Immunogenic composition
CN105441319A (zh) * 2015-07-29 2016-03-30 东莞东华医院有限公司 一种围产期孕妇b群链球菌采样管及其制备方法
CN109890415B (zh) 2016-08-05 2023-04-04 圣诺菲·帕斯图尔公司 多价肺炎球菌多糖-蛋白质缀合物组合物
EP3493837B1 (en) 2016-08-05 2022-08-31 Sanofi Pasteur, Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
MX2020008198A (es) 2018-02-05 2020-09-22 Sanofi Pasteur Inc Composicion del conjugado proteina-polisacarido multivalente neumococica.
CA3087572A1 (en) 2018-02-05 2019-08-08 Sanofi Pasteur Inc. Multivalent pneumococcal polysaccharide-protein conjugate composition
BR112020021296A2 (pt) 2018-04-18 2021-01-26 Sk Bioscience Co., Ltd. polissacarídeo capsular de streptococcus pneumoniae e conjugado imunogênico do mesmo

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
ES2108278T3 (es) 1992-06-25 1997-12-16 Smithkline Beecham Biolog Composicion de vacuna con coadyuvantes.
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
WO1994021292A1 (en) 1993-03-23 1994-09-29 Smithkline Beecham Biologicals (S.A.) Vaccine compositions containing 3-o deacylated monophosphoryl lipid a
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
ATE328890T1 (de) 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
CA2253549C (en) 1996-06-18 2005-10-25 Alza Corporation Device for enhancing transdermal agent delivery or sampling
EP0942983B2 (en) 1996-10-31 2014-09-10 Human Genome Sciences, Inc. Streptococcus pneumoniae antigens and vaccines
US5980898A (en) 1996-11-14 1999-11-09 The United States Of America As Represented By The U.S. Army Medical Research & Material Command Adjuvant for transcutaneous immunization
KR100453132B1 (ko) 1996-12-20 2004-10-15 앨자 코포레이션 경피 약제 플럭스를 향상시키기 위한 장치 및 방법
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
EP1009382B1 (en) 1997-09-05 2003-06-18 GlaxoSmithKline Biologicals S.A. Oil in water emulsions containing saponins
CN1291233A (zh) 1997-09-24 2001-04-11 美国明尼苏达州大学 来自肺炎链球菌之人类补体c3降解蛋白酶
WO1999027961A1 (en) 1997-12-02 1999-06-10 Powderject Vaccines, Inc. Transdermal delivery of particulate vaccine compositions
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
IL142017A0 (en) 1998-09-24 2002-03-10 Univ Minnesota Human complement c3-degrading polypeptide from streptococcus pneumoniae
GB2359228A (en) 1998-11-17 2001-08-15 Schlumberger Technology Corp Transmitting information over a communication link
AU776828B2 (en) * 1998-12-21 2004-09-23 Medimmune, Llc Streptococcus pneumoniae proteins and immunogenic fragments for vaccines
BR9916477A (pt) * 1998-12-23 2004-06-22 Shire Biochem Inc Polinucleotìdeo isolado, polinucleotìdeo quimérico, composição de vacina e uso desta composição compreendendo os polinucleotìdeos
US6319224B1 (en) 1999-08-20 2001-11-20 Bioject Medical Technologies Inc. Intradermal injection system for injecting DNA-based injectables into humans
CA2382795A1 (en) * 1999-08-25 2001-03-01 Medimmune, Inc. Homologs of a pneumococcal protein and fragments for vaccines
US6494865B1 (en) 1999-10-14 2002-12-17 Becton Dickinson And Company Intradermal delivery device including a needle assembly
NZ553554A (en) * 2000-06-20 2008-11-28 Id Biomedical Corp Streptococcus antigens
EP1186299A1 (en) * 2000-09-12 2002-03-13 Universitair Medisch Centrum Utrecht The diagnosis, prevention, and/or succesful treatment of atherosclerosis, infectious diseases, and disturbances in the immune system
JP5442173B2 (ja) * 2000-09-14 2014-03-12 敏一 中村 筋萎縮性側索硬化症治療剤
GB0022742D0 (en) * 2000-09-15 2000-11-01 Smithkline Beecham Biolog Vaccine
EP1188446B1 (en) * 2000-09-15 2009-08-05 Institut Pasteur Proteinaceous vectors for molecule delivery to CD11b expressing cells
ATE384072T1 (de) 2000-09-26 2008-02-15 Idera Pharmaceuticals Inc Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
JPWO2003050782A1 (ja) 2001-12-12 2005-04-21 株式会社法学館 演習問題出題システム
US7262024B2 (en) * 2001-12-20 2007-08-28 Id Biomedical Corporation Streptococcus antigens
PT1748791E (pt) 2004-05-11 2010-07-15 Staat Der Nederlanden Vert Doo Los de neisseria meningitidis lgtb utlizados como adjuvantes
CN100433358C (zh) * 2005-12-22 2008-11-12 友达光电股份有限公司 双面显示装置
WO2009012588A1 (en) 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies

Also Published As

Publication number Publication date
KR20130038237A (ko) 2013-04-17
DK2544711T3 (en) 2016-03-07
EA201290689A1 (ru) 2013-08-30
AU2011226119A1 (en) 2012-11-01
CN102869376A (zh) 2013-01-09
EP2544711A1 (en) 2013-01-16
US9314518B2 (en) 2016-04-19
ZA201206636B (en) 2014-02-26
SMT201600059B (it) 2016-04-29
BR112012022360A2 (pt) 2019-09-24
EP2544711B1 (en) 2016-01-06
JP2013521322A (ja) 2013-06-10
ES2562979T3 (es) 2016-03-09
HUE027103T2 (en) 2016-08-29
PT2544711E (pt) 2016-03-22
AU2011226119B2 (en) 2014-04-24
EA023702B1 (ru) 2016-07-29
SI2544711T1 (sl) 2016-03-31
CA2791946A1 (en) 2011-09-15
SG183474A1 (en) 2012-09-27
PL2544711T3 (pl) 2016-06-30
US20140205634A1 (en) 2014-07-24
WO2011110570A1 (en) 2011-09-15
RS54593B1 (en) 2016-08-31
GB201003920D0 (en) 2010-04-21
MX2012010386A (es) 2012-10-10
JP5968229B2 (ja) 2016-08-10
HRP20160150T1 (en) 2016-03-11
US20120328659A1 (en) 2012-12-27

Similar Documents

Publication Publication Date Title
CY1117238T1 (el) Θεραπεια στρεπτοκοκκικων λοιμωξεων
CY1123951T1 (el) Μια συνθεση που περιλαμβανει ενα αντιβιοτικο μη πεπτιδιου και μια cysteamine
CY1122671T1 (el) Θεραπευτικως δραστικες ενωσεις και οι μεθοδοι χρησεις αυτων
CY1124298T1 (el) Φενφλουραμινη για χρηση στην θεραπευτικη αντιμετωπιση του συνδρομου dravet
CY1122480T1 (el) Μεθυλικη βαρδοξολονη για τη θεραπεια παχυσαρκιας
CY1122187T1 (el) Αντιγονικη συνθεση μυκοβακτηριου
MX2016008013A (es) Conjugados de farmacos anticuerpo (adcs) con inhibidores de ksp.
EA200701511A1 (ru) Фармацевтические композиции бендамустина, предназначенные для лиофилизации
BR112014016805A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
MD4577B1 (ro) Compoziţii masticabile de uz veterinar care conţin agent activ izoxazolinic şi utilizarea acestora în tratamentul sau prevenirea unei infestări sau infecţii parazitare
BR112015013123A2 (pt) inibidores de beta-lactamase
MX2014012247A (es) Bacterias probioticas.
BR112016006978A2 (pt) inibidores de tirosina quinase de bruton
MX341883B (es) Composicion farmaceutica para el tratamiento y prevencion de canceres.
BR112016002287A2 (pt) compostos terapeuticamente ativos e seus métodos de uso
EA201100335A1 (ru) Производные пурина для применения при лечении связанных с fab заболеваний
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
CY1121628T1 (el) 7-βενζυλ-4-(2-μεθυλοβενζυλ)-2,4,6,7,8,9-εξαϋδροϊμιδαζο[1,2-α]πυριδο[3,4-ε]πυριμιδιν-5(1η)-ονη, αλατα αυτης και μεθοδοι χρησης
CY1113671T1 (el) Θεραπεια γνωστικων διαταραχων με (r)-7-χλωρο-ν-(κινουκλιδιν-3-υλ)βενζο[b]θειοφαινο-2-καρβοξαμιδιο και τα φαρμακευτικως αποδεκτα αλατα του
MX2013003638A (es) Tratamiento en combinacion para rosacea.
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
CY1122635T1 (el) Συζευγμα ενος θραυσματος ενος κυτταρικου τοιχωματος ενος βακτηριου και μια βλεννοπολυσακχαριδικη ουσια-φορεας, και χρησεις στην ιατρικη εξ αυτων
BR112014000810A8 (pt) Métodos para tratamento de inflamação e hipertensão com scavengers de gama-cetoaldeídos
BR112013033759A8 (pt) Forma de dosagem unitária de um gel de base aquosa de metronidazol mucoadesivo e uso relacionado ao gel de base aquosa de metronidazol
BR112013018264A2 (pt) "peptídeos sintéticos, uso dos mesmos e composição farmacêutica"